← The Wire
PTCTNasdaq
PTC THERAPEUTICS, INC.
Pharmaceutical Preparations · DE · CIK 1070081
Develops and commercializes therapeutics for rare diseases and challenging conditions
red 8-K · 90d
$6.23B
Market cap
$81.57
Last close
-3.4%
1D
+0.8%
5D
4.3M
Volume
Price · last 39 sessions+24.6%
May 4L $64.49 · H $84.51Jun 29
231
Total filings
Jun 18, 2026
Last filing
12/31
Fiscal year end
8-KMaterial Agreement · New Debt / ObligationJun 18, 20268-KCompany UpdateJun 16, 20268-KExecutive ChangeJun 9, 20268-KShareholder VoteJun 5, 202610-Q10-QMay 7, 20268-KResults of Operations · Reg FD DisclosureMay 7, 20268-KReg FD DisclosureApr 28, 2026DEFA14ADEFA14AApr 20, 2026DEF 14ADEF 14AApr 20, 20268-KExecutive Change · Reg FD DisclosureMar 25, 202610-K10-KFeb 19, 20268-KResults of Operations · Reg FD DisclosureFeb 19, 20268-KReg FD DisclosureFeb 12, 20268-KResults of Operations · Reg FD DisclosureJan 12, 20268-KMaterial AgreementDec 29, 202510-Q10-QNov 4, 20258-KResults of Operations · Reg FD DisclosureNov 4, 20258-KReg FD DisclosureAug 19, 202510-Q10-QAug 7, 20258-KMaterial AgreementAug 7, 20258-KResults of Operations · Reg FD DisclosureAug 7, 20258-KReg FD DisclosureJul 28, 20258-KShareholder VoteJun 17, 202510-Q10-QMay 6, 20258-KResults of Operations · Reg FD DisclosureMay 6, 20258-KReg FD DisclosureMay 5, 2025DEFA14ADEFA14AApr 30, 2025DEF 14ADEF 14AApr 30, 20258-KReg FD DisclosureMar 28, 202510-K10-KFeb 27, 20258-KResults of Operations · Reg FD DisclosureFeb 27, 20258-KResults of Operations · Reg FD DisclosureJan 13, 20258-KMaterial Agreement · New Debt / ObligationJan 3, 20258-KMaterial Agreement · Reg FD DisclosureDec 2, 20248-KMaterial Agreement · Reg FD DisclosureNov 27, 202410-Q10-QNov 7, 20248-KResults of Operations · Reg FD DisclosureNov 7, 20248-KReg FD DisclosureOct 18, 202410-Q10-QAug 8, 20248-KResults of Operations · Reg FD DisclosureAug 8, 20248-KReg FD DisclosureJun 28, 20248-KMaterial Agreement · Shareholder VoteJun 20, 20248-KReg FD DisclosureMay 20, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 202410-Q10-QApr 25, 20248-KResults of Operations · Reg FD DisclosureApr 25, 202410-K10-KFeb 29, 20248-KResults of Operations · Reg FD DisclosureFeb 29, 2024SC 13GSC 13GFeb 14, 20248-KReg FD DisclosureJan 25, 20248-KResults of Operations · Reg FD DisclosureJan 8, 2024SC 13GPRIMARY DOCUMENTOct 30, 202310-Q10-QOct 26, 20238-KResults of Operations · Reg FD DisclosureOct 26, 20238-KAgreement TerminatedOct 19, 20238-KMaterial Agreement · Reg FD DisclosureOct 19, 20238-KExit / Disposal Costs · Reg FD DisclosureSep 28, 20238-KCompany UpdateSep 22, 20238-KReg FD Disclosure · Company UpdateSep 15, 202310-Q10-QAug 3, 20238-KResults of Operations · Reg FD DisclosureAug 3, 20238-KReg FD Disclosure · Company UpdateJul 19, 20238-KExecutive ChangeJul 17, 20238-KReg FD DisclosureJun 21, 20238-KShareholder VoteJun 6, 20238-KExecutive Change · Exit / Disposal CostsMay 23, 20238-KReg FD Disclosure · Company UpdateMay 17, 202310-Q10-QApr 27, 20238-KResults of Operations · Reg FD DisclosureApr 27, 2023DEFA14ADEFA14AApr 26, 2023DEF 14ADEF 14AApr 26, 20238-KExecutive ChangeApr 18, 20238-KExecutive Change · Reg FD DisclosureMar 24, 202310-K/AFORM 10-K/AMar 8, 202310-K10-KFeb 21, 20238-KResults of Operations · Reg FD DisclosureFeb 21, 20238-KResults of Operations · Reg FD DisclosureJan 9, 20238-KExecutive Change · Bylaw AmendmentDec 6, 202210-Q10-QOct 27, 2022
Insider Activity
In the 90 days to Mar 12, 2026: 10 sold $14.8M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 12, 2026 | Klein Matthew B.CHIEF EXECUTIVE OFFICER | Sell | 2,662 | $64.08 | $171K |
| Mar 10, 2026 | Okey StephanieDirector | Sell | 14,000 | $70.00 | $980K |
| Mar 10, 2026 | Okey StephanieDirector | Sell | 1,167 | $70.00 | $82K |
| Mar 5, 2026 | Golden Lee ScottEVP & CHIEF MEDICAL OFFICER | Sell | 10,000 | $63.38 | $634K |
| Mar 5, 2026 | Okey StephanieDirector | Sell | 6,333 | $63.38 | $401K |
| Mar 5, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sell | 3,989 | $63.38 | $253K |
| Feb 19, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sell | 1,629 | $69.82 | $114K |
| Feb 19, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sell | 590 | $69.82 | $41K |
| Feb 19, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sell | 588 | $68.54 | $40K |
| Feb 19, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sell | 212 | $68.54 | $15K |
| Feb 18, 2026 | Klein Matthew B.CHIEF EXECUTIVE OFFICER | Sell | 7,371 | $69.36 | $511K |
| Feb 18, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sell | 3,081 | $69.36 | $214K |
| Feb 18, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sell | 3,056 | $69.36 | $212K |
| Feb 18, 2026 | Pauwels EricCHIEF BUSINESS OFFICER | Sell | 3,019 | $69.36 | $209K |
| Feb 18, 2026 | Gravier PierreCHIEF FINANCIAL OFFICER | Sell | 2,992 | $69.36 | $208K |
| Feb 18, 2026 | Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER | Sell | 2,494 | $69.36 | $173K |
| Feb 18, 2026 | Golden Lee ScottEVP & CHIEF MEDICAL OFFICER | Sell | 2,484 | $69.36 | $172K |
| Feb 18, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | Sell | 65 | $69.36 | $5K |
| Feb 17, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sell | 2,811 | $69.29 | $195K |
| Feb 17, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Sell | 2 | $70.13 | $140 |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance